Prostate cancer is the first male cancer in Congo. Its management requires the use of radiotherapy after surgery. The indication for radiation therapy depends on certain factors with poor prognosis including marginal resection limits, seminal vesicle involvement, capsular capture or pelvic lymph node involvement.

Adjuvant radiation therapy prevents local recurrence.

The current unavailability of radiotherapy in Congo forces patients at the University Hospital of Brazzaville to travel abroad to benefit from this type of treatment, which is essential for the management of operated prostate cancer.

After radiotherapy, the therapeutic response should be assessed and patients reassured of the possibility of complete remission or cure.

The patients selected in this study had all benefited from intensity-modulated radiotherapy (IMRT or MRI) or Irradiation with Volumetric Intensity Modulation by Arc Therapy in acronym VMAT.

It seemed appropriate to us to take stock of patients treated with radiotherapy abroad for prostate cancer.

Keywords: Response; Radiotherapy; Cancer; Prostate; Foreign

References

1. Bolla M., et al. “Postoperative radiotherapy after radical prostatectomy : A randomized controlled trial (EORTC trial 22911)”. Lancet 366 (2005): 572-578.
2. Sella T., et al. “Suspected local recurrence after radical prostatectomy : Endorectal coil MR imaging”. Radiology 231 (2004): 379-385.
3. Kane CJ., et al. “Limited value of bone scintigraphy and camputed tomography in assessing biochemical failure rate after radical prostatectomy”. Urology 61 (2003): 607-611.
4. Oyama N., et al. “11C-Acetate PET imaging of prostate cancer : Detection of recurrent disease at PSA relapse”. The Journal of Nuclear Medicine 44 (2003): 549-555.
5. Djavan B., et al. “PSA progression following radical prostatectomy and radiation therapy : New standards in the new millenium”. European Urology 43 (2003): 12-27.
6. Stephenson AJ., et al. “Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy”. JAMA 291 (2004): 1325-1332.
7. Freedland SJ., et al. “Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy”. JAMA 249 (2005): 433-439.
8. Roehl KA., et al. “Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients : Long-term results”. Journal of Urology 172 (2004): 910-914.
9. Ward JF and Moul JW. “Biochemical recurrence after definitive prostate cancer therapy. Part I : Definition and localizing biochemical recurrence of prostate cancer”. Current Opinion in Urology 15 (2005): 181-186.
10. D'Amico AV., et al. “Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy”. Journal of the National Cancer Institute 95 (2003): 1376-1383.
11. Raj GV., et al. “Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy”. Cancer 94 (2002): 987-996.
12. Gronau E., et al. “Prostate cancer relapse after therapy with curative intention : A diagnostic and therapeutic dilemma". Onkologie 28 (2005): 361-366.
13. Oh J., et al. “Current follow-up strategies after radical prostatectomy : A survey of American Urological Association Urologists”. Journal of Urology 161 (1999): 520-523.
14. Ornstein DK., et al. “Evaluation and management of men whose radical prostatectomy failed : Results of an international survey”. Urology 52 (1998): 1047-1054.

Citation

Citation: Nkoua Epala Brice Aymard., et al. “Therapeutic Response of Congolese Patients Treated with Radiotherapy Abroad for Prostate Cancer”.Acta Scientific Cancer Biology 8.8 (2024): 03-07.

Copyright

Copyright: © 2024 Nkoua Epala Brice Aymard., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.